Sodium Zirconium Cyclosilicate in HFrEF and Hyperkalemia
Year: 2024
Type: article
Abstract: BACKGROUND: Mineralocorticoid receptor antagonists (MRAs) improve outcomes in patients with heart failure and reduced ejection fraction (HFrEF). However, MRAs are often underused because of hyperkalemia concerns. OBJECTIVES: The purpose of this study was to assess whether sodium zirconium cyclosilicate (SZC), a nonabsorbed crystal that traps and rapidly lowers potassium, enables MRA use in patients with HFrEF and prevalent hyperkalemia (or at high risk). METHODS: REALIZE-K is a prospective, double-blind, placebo-controlled trial in patients with HFrEF (NYHA functional class II-IV; left ventricular ejection fraction ≤40%), optimal therapy (except MRA), and prevalent hyperkalemia (or at high risk). During the open-label run-in, all participants underwent protocol-mandated spironolactone titration (target: 50 mg daily); those with prevalent (cohort 1) or incident (cohort 2) hyperkalemia during titration started SZC. Participants achieving normokalemia while on spironolactone ≥25 mg daily were randomized to continuing SZC or matching placebo for 6 months. The primary composite endpoint was proportion of participants with optimal response (normokalemia, on spironolactone ≥25 mg daily, no rescue for hyperkalemia [months 1-6]). RESULTS: , 38% atrial fibrillation/flutter), high N-terminal pro B-type natriuretic peptide (median 1,136 pg/mL), and high HFrEF therapy use (64% sacubitril/valsartan, 96% beta-blocker, 42% sodium glucose co-transporter 2 inhibitor). At randomization, 78% were receiving spironolactone 50 mg daily. CONCLUSIONS: REALIZE-K is the first trial to evaluate whether SZC can enable rapid and safe MRA optimization and long-term continuation in patients with HFrEF and prevalent/high risk of hyperkalemia. (Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients with Symptomatic HFrEF Receiving Spironolactone [REALIZE-K]; NCT04676646).
Source: JACC Heart Failure
Authors: Mikhail N. Kosiborod, David Cherney, Kim Connelly, Akshay S. Desai, Patrícia O. Guimarães, Luca Kuthi, Anuradha Lala, Vagner Madrini, Bela Merkely, Julio Nuñez Villota, Iain Squire, Jeffrey M. Testani, Jan Vaclavik, Subodh Verma, Jerzy Wranicz, Magnus Dahl, James M. Eudicone, Lovisa Friberg, Mark C. Petrie
Institutions: Saint Luke's Hospital, University of Missouri–Kansas City, Mount Sinai Hospital, University Health Network, University of Toronto, St. Michael's Hospital, Brigham and Women's Hospital, Semmelweis University, Mount Sinai Hospital, Hospital Israelita Albert Einstein, Hospital Clínico Universitario de Valencia, Glenfield Hospital, University Hospitals of Leicester NHS Trust, Yale University, University of Ostrava, University Hospital Ostrava, Unity Health Toronto, Medical University of Lodz, Centralny Szpital Kliniczny, AstraZeneca (Sweden), AstraZeneca (United States), Glasgow Royal Infirmary, University of Glasgow
Language: English
Subfield: Nephrology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,750
OpenAlex ID: W4396865545
